Podcasts about Alexion Pharmaceuticals

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EMS865. CME/AAPA/IPCE credit will be available until May 5, 2026.Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies & Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Neurological Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EMS865. CME/AAPA/IPCE credit will be available until May 5, 2026.Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies & Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Neurological Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EMS865. CME/AAPA/IPCE credit will be available until May 5, 2026.Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies & Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Neurological Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EMS865. CME/AAPA/IPCE credit will be available until May 5, 2026.Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies & Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Neurological Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EMS865. CME/AAPA/IPCE credit will be available until May 5, 2026.Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies & Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Neurological Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EMS865. CME/AAPA/IPCE credit will be available until May 5, 2026.Bridging Gaps, Shaping Lifelong NF1 Care: Team Strategies & Management Choices With MEK Inhibitors Across the Pediatric-to-Adult Care Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Neurological Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

Synopsis: In this episode, host Rahul Chaturvedi interviews Sarah Boyce, President & CEO of Avidity Biosciences, as she shares her dynamic journey from big pharma to leading groundbreaking advancements in RNA therapeutics. Sarah delves into overcoming drug delivery challenges, the transformative potential of genetic medicine, and Avidity's mission to redefine rare disease treatments. She also offers candid insights on leadership, the importance of cultivating a strong company culture, and balancing personal well-being for long-term success. This episode is essential for those eager to explore the future of biotech and the next wave of medical innovation. Biography: Sarah Boyce joined Avidity as President and Chief Executive Officer and a member of the Board of Directors in October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah's tenure at Avidity has been marked by transformative leadership, starting with the company's successful Series C funding round and IPO. She continues to drive the company's evolution from a research and development entity to a biopharmaceutical company through the advancement of three therapies into clinical development and the expansion of the broad utility of the company's proprietary RNA technology. Prior to joining Avidity, Sarah held the position of president and a member of the board of directors of Akcea Therapeutics. She previously held executive roles in business development and global operations for leading life sciences companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Sarah was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and has been named one of Fiercest Women in Life Sciences. Sarah currently serves as a member of the board of directors at OmniAb, Inc., Contineum Therapeutics, Inc., and Abcuro, Inc. Sarah holds a BSc (Hons) degree in microbiology from the University of Manchester, England.

This episode of Health Care Beat kicks off a two-part series in collaboration with Seyfarth's Global Immigration practice. Co-hosts Chris DeMeo and Amanda Genovese are joined by Daniela Mayer, Counsel in the firm's Boston office, as well as Fred Chereau, Senior Vice President of Strategy and Business Development at Alexion Pharmaceuticals. The group discusses Fred's career trajectory and the value of leveraging immigration programs to secure talent in the health care, life sciences, and pharmaceutical industries.

Jack Quinn: Head, State Government Affairs for Regeneron Pharmaceuticals Jack Quinn leads Regeneron Pharmaceutical's state policy, advocacy, regulatory, and political activity across all 50 states. Born-and-raised in Buffalo, NY, Jack attended Siena College and SUNY Buffalo Law School.  After being admitted to the New York Bar, Quinn served as a prosecutor for the Erie County District Attorneys Office. Elected to the New York State Assembly in 2004.  Jack served six years (2005-2010) in the legislature representing the 146th Assembly District (Erie County).  A member of the Republican Party, Quinn served on the Assembly Judiciary, Higher Education, Banks, Transportation and Ethics Committees. Following his six-year tenure in the Assembly, Jack has spent the last 14 years lobbying across 35+ states for several pharmaceutical manufacturers (Allergan, Vertex, and Sanofi) as well as ExxonMobil.  In his two prior roles, Quinn led State Government Relations teams for Alexion Pharmaceuticals and Regence BlueCross BlueShield. In addition to his role with Regeneron, Jack has also spent the last six years serving as a Northeast Charter School Network (NESCN) board member.  NESCN is a non-profit organization that advocates for pro-charter school legislative policies on behalf of over 150 school across New York and Connecticut.  Jack and his family live in Manhattan.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025.Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alexion Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025.Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alexion Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025.Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alexion Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025.Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alexion Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025.Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alexion Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025.Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alexion Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025.Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alexion Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025.Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alexion Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025.Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alexion Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025.Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alexion Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

William A. Lumpkin (Will) is a devoted husband to Layla, a proud father to Ailey, Sage, and Liam, and a purpose-driven leader with a passion for delivering significant impact through high-performing teams. Will serves as Vice President of Sales at Agios Pharmaceuticals in Cambridge, MA, where he leads a team dedicated to providing disease education and access to first and best-in-class solutions for underserved patient populations affected by chronic hemolytic anemia. Prior to Agios, William was Head of New Product Strategy and Business Development at Alexion Pharmaceuticals, Chief of Staff to the Chief Commercial and Global Operations Officer, and the Commercial Integration lead for Alexion into Astra Zeneca rare disease. His innovative solutions earned him Guiding Star and Excellence Awards. With a diverse background spanning leadership across functional disciplines, including finance, sales, marketing, and strategy, at Baxter, Baxalta, Shire, and Takeda, Will has demonstrated his ability to build and lead teams that operate with a sense of urgency in service of others. His professional journey began in finance at Procter & Gamble and includes time as a lecturer at UNC Kenan Flagler School of Business. Will holds an MBA from the University of Chicago Booth School of Business and a Bachelor of Science in Finance from Indiana University, where he excelled as a four-time letterman, senior captain of the Hoosier football team, and President of the Alpha Chapter, Kappa Alpha Psi Fraternity, Inc. Originally from Dayton, Ohio, Will and his family reside in Houston, where he remains actively engaged in community leadership roles, including serving on the Hermann Park Conservatory Board and as a Senior Fellow at the American Leadership Forum. What you'll learn on this episode:  The power of purpose-driven leadership The impact of values on team building and work focus How to connect individual impact to organizational goals The significant role of communication and active listening Strategies for continuous leadership development and growth The importance of authenticity, honesty, and integrity in leadership Additional Resources: William's LinkedIn  Agios Pharmaceuticals' Website >> https://agios.com/  Learn more about PK Deficiency >>  https://www.knowpkdeficiency.com/ Learn more about opportunities to work with Agios and search their open positions below: https://phe.tbe.taleo.net/phe03/ats/careers/v2/searchResults?org=AGIOS&cws=37 

This episode of the CBIA BizCast is the second of a two-part discussion on a key issue in Connecticut and across the country—whole genome sequencing. In this episode Paul Pescatello, CBIA senior counsel and executive director of the Connecticut Bioscience Growth Council speaks with Dr. Adam Matson and Dr. Louisa Kalsner from Connecticut Children's. Dr. Matson is a neonatologist and lead researcher for Genomic Sequencing in the neonatal and pediatric population at the hospital. And Dr. Kalsner is the division head for Genetics. Doctors Mtson and Kalsner highlight the importance of whole genome sequencing in both research and clinical settings. They also discuss the technology's future and its value to patients, caregivers, and families. Please click here for part one of our discussion on whole genome sequencing with Alexion Pharmaceuticals, Inc.'s Dr. Tom Defay: https://www.cbia.com/news/issues-policies/cbia-bizcast-whole-genome-sequencing

This episode of the CBIA BizCast is part one of a two-part discussion on a key issue in Connecticut and across the country— whole genome sequencing. In this episode Paul Pescatello, CBIA senior counsel and executive director of the Connecticut Bioscience Growth Council speaks with Dr. Tom Defay. Defay is a computational biologist and Deputy Head Diagnostics Strategy & Development at New Haven-based Alexion Pharmaceuticals, Inc. He details how the technology is valuable to patients for early diagnosis and treatment, and a cost saver for our healthcare system. This legislative session a bill to promote expansion of whole genome sequencing, HB 5367, An Act Concerning Medicaid Coverage of Rapid Whole Genome Sequencing for Critically Ill Patients, is before the Connecticut General Assembly. This is important legislation and it is strongly supported by the CBIA Bioscience Growth Council.

This 45-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology and treatment of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/Contact: CEServices@academycme.orgCopyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This 15-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system-pathophysiology/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/Contact: CEServices@academycme.orgCopyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This 30-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the treatment of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system-treatment-options/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.org Copyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from argenx US, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJames F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.Faculty/PlannerAmy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.Faculty/PlannerClaire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJames D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.Data Safety Monitoring Board for Sanofi.Co-Chair/PlannerSabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

ONCE UPON A GENE - EPISODE 158 Medical Student - Urvi Gupta Joins the Global Genes Rare Compassion Program with Alexions Patient Advocacy Champion Wendy Erler Wendy Erler is passionate about the caregiver and patient voice being at the forefront of her work at Alexion Pharmaceuticals. Urvi Gupta is a second year medical student, working with the rare disease community to shape her professional path forward in the medical field. In this episode, I talk with Wendy Erler and Urvi Gupta about the Global Genes Rare Compassion Program.  EPISODE HIGHLIGHTS Wendy, can you tell us about yourself? I lead the patient advocacy team at Alexion, a pharmaceutical company focused on rare diseases. We work with physicians, patients, families and caregivers and my job is focused on elevating that partnership and bringing the patient and caregiver voice into everything we do.  Urvi, can you share how you became involved with the rare disease community? In a class called Clinical Correlation, we had a patient visit and they mentioned the Global Genes Rare Compassion Program, which matches up medical students with patients who have rare diseases to allow them to learn from each other. I've had three patient partners through that program and it's been amazing and inspiring to network with everyone in the rare disease community.  Urvi, how essential do you think it is to experience a true doctor-patient relationship already? So many patients say their course of treatment varies greatly based on how well their doctor listens to them. I think that's so important when it comes to rare diseases because it's not something you see often and when a patient presents a unique set of symptoms, they can't be brushed off. It's been helpful to experience and come to understand that the patient's perspective is the one that matters and what will help get a diagnosis.  Urvi, in what ways are you interested in raising awareness of the rare disease community? I would advise all medical students interested in rare disease to join the Global Genes Rare Compassion Program. There are a lot of other rare disease organizations always looking for help and there's likely a perspective you can offer.  LINKS & RESOURCES MENTIONED Global Genes Rare Compassion Program https://globalgenes.org/compassion/ Alexion Pharmaceuticals https://alexion.com/ Connor B. Judge Foundation https://www.connorbjudgefoundation.org/ CONNECT WITH WENDY & URVI Wendy Erler https://www.linkedin.com/in/wendyerler/ Urvi Gupta https://www.linkedin.com/in/urvigupta1/ TUNE INTO THE ONCE UPON A GENE PODCAST Spotify https://open.spotify.com/show/5Htr9lt5vXGG3ac6enxLQ7 Apple Podcasts https://podcasts.apple.com/us/podcast/once-upon-a-gene/id1485249347 Stitcher https://www.stitcher.com/podcast/once-upon-a-gene Overcast https://overcast.fm/itunes1485249347/once-upon-a-gene CONNECT WITH EFFIE PARKS Website https://effieparks.com/ Twitter https://twitter.com/OnceUponAGene Instagram https://www.instagram.com/onceuponagene.podcast/?hl=en Built Ford Tough Facebook Group https://www.facebook.com/groups/1877643259173346/

In today's episode, I chat with Rob Salafia. What happens when you combine a successful career in the performing arts with over 2 decades as a top leadership development executive? You get Rob, who early in his career, travelled the globe as a performing artist offering his one person show in theatres, festivals and select street venues. He used storytelling, tap dancing, comic characters and wire waking to engage and delight audiences. Fifteen years later, he earned a Master's degree in business while working full time at Boston University, and transitioned into corporate learning. He now runs his own company - Protagonist Consulting Group - and is a lecturer and executive coach at the MIT Sloan School of Management.In the discussion, Rob & I cover a lot of fertile ground, beginning with his background & experiences in the performing arts. And now as an executive coach. We chat about society's broader shift to virtual & Rob shares how he helps leaders develop their executive presence, authenticity and storytelling skills through transformational learning experiences. It was such a pleasure connecting with Rob. And I hope you enjoy it. Rob SalafiaRob is the author of – Leading From Your Best Self: Develop Your Executive Poise, Presence and Influence to Maximize Your Potential (McGraw-Hill). As an executive coach, Rob finds great satisfaction in guiding leaders through transitions to more senior roles, as well as coaching senior executives and leadership teams to enhance team effectiveness and prepare for strategic presentations. Rob is a lecturer in MIT Sloan School of Management and an MIT Leadership Centre Master Executive Coach. He is certified in the PRINT Assessment to reveal one's Unconscious Motivators. Over the past 20 years Rob has worked with a multitude of Fortune 500 companies in the capacity as a speaker, executive coach, learning partner and workshop facilitator. These include, Harvard Business School, Alexion Pharmaceuticals, PepsiCo, TJX, Publicis Sapient, ING Bank, NN Group, News Corp, Sony Music Entertainment, Thought Ensemble, Metro AG, Philips International, Alliance Bernstein, and Fidelity Investments. LinkedInThinking Inside the BoxConstraints drive innovation. We tackle the most complex issues related to work & culture. And if you enjoy the work we're doing here, consider giving us a 5-star rating, leaving a comment & subscribing. It ensures you get updated whenever we release new content & really helps amplify our message. LinkedInInstagramTwitterWebsiteApple PodcastsGoogle PodcastsSpotifyStitcherPocket CastMatt BurnsMatt Burns is an award-winning executive, social entrepreneur and speaker. He believes in the power of community, simplicity & technology.LinkedInTwitter

This accredited CME activity, led by Satheesh Chonat, MD, Assistant Professor at Emory University School of Medicine and hematologist-oncologist at the Pediatric Hematology Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, highlights the latest real world data focused on paroxysmal nocturnal hemoglobinuria (PNH). Dr Chonat also provides expert analysis of the data's clinical relevance for members of the care team to help them manage patients with PNH they may encounter with this rare condition. PNH is a rare, acquired blood disease characterized by hemolytic anemia, bone marrow failure, thrombosis, and fatigue. Supported by an educational grant from Alexion Pharmaceuticals, Inc. For complete activity information and to obtain CME credit, please go to https://checkrare.com/learning-center/courses/

This week on Pharm5: FDA and DEA warn of online CII sales Ultomiris (ravulizumab) improves ADLs and QOL for up to 60 weeks in patients with myasthenia gravis Fidaxomicin's biomolecular specificity to C. diffunveiled Sotrovimab has lost its EUA for treatment of COVID-19 Results from Phase II of ASHP's Residency Match Connect with us! Listen to our podcast: Pharm5 Watch us on TikTok: @LizHearnPharmD Follow us on Twitter: @LizHearnPharmD References: McCarthy L-J. FDA and DEA warn online pharmacies illegally selling Adderall to consumers. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-and-dea-warn-online-pharmacies-illegally-selling-adderall-consumers. Published April 12, 2022. Accessed April 12, 2022. Ultomiris® (ravulizumab-CWVZ) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks. AstraZeneca US. https://www.astrazeneca-us.com/media/press-releases/2022/ultomiris-demonstrated-sustained-improvements-in-functional-activities-and-quality-of-life-in-adults-with-generalized-myasthenia-gravis-through-60-weeks.html. Published April 6, 2022. Accessed April 14, 2022. Ultomiris (ravulizumab-CWVZ). Package insert. Alexion Pharmaceuticals, Inc; 2018. Cao X, Boyaci H, Chen J, Bao Y, Landick R, Campbell EA. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile. Nature. April 2022. doi:10.1038/s41586-022-04545-z Rockefeller University. How a narrow-spectrum antibiotic takes aim at C. Diff. EurekAlert! https://www.eurekalert.org/news-releases/948950. Published April 6, 2022. Accessed April 14, 2022. Center for Drug Evaluation and Research. FDA updates Sotrovimab Emergency Use Authorization. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization. Published April 5, 2022. Accessed April 14, 2022. Person, Kavya B AM. Worldwide covid cases surpass 500 mln as Omicron variant BA.2 surges. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/worldwide-covid-cases-surpass-500-mln-omicron-variant-ba2-surges-2022-04-14/. Published April 14, 2022. Accessed April 14, 2022. Schedule of dates. ASHP Match | Schedule. https://natmatch.com/ashprmp/schedule.html. Published April 13, 2022. Accessed April 14, 2022. ASHP Match Statistics. ASHP Match | Statistics of the Match. https://natmatch.com/ashprmp/stats.html. Published April 13, 2022. Accessed April 14, 2022.

Ed is a leadership coach, team coach, strategist, podcast host, and author who helps successful leaders build their self-awareness so they can self-manage more effectively.BLUE CHIP CLIENTSHis clients include Alexion Pharmaceuticals, Biogen, Blue Cross Blue Shield, Bright Horizons, Cabot Risk Strategies, Constant Contact, Dyax Pharmaceuticals, Eaton Vance, edX, Galderma, GMAC, Harvard Pilgrim Health Care, Healthedge, ILPA, Johnson & Johnson, Keurig, Kronos, Lahey Health, Ortholite, Safety Partners, Suffolk, and Vertex Pharmaceuticals. LEADERSHIP PROGRESSIONHe held leadership roles at Iron Mountain, the (former) Federated Department Stores, and the (former) May Department Stores. As a coach and as a human resources executive, I have supported leaders in a variety of high-impact business areas including account management, engineering, finance, human resources, information technology, legal, marketing, product development, product management, operations, and sales.INDUSTRY LEADERSHIPHe also coached international executives in the Program for Leadership Development at Harvard Business School. In my former role as President of the New England Chapter of the International Coach Federation (ICF), I was deeply involved in advancing the coaching profession and serving as a non-profit leader. He is a Professional Certified Coach with the International Coach Federation and a Board Certified Coach with the Center for Credentialing and Education. I am also a volunteer coach for the Coaching for Leadership and Teamwork Program at Babson College.Ed: https://www.linkedin.com/in/edevarts/website: https://www.excellius.comPodcast: http://bebraveatwork.com/

he event featured experts including Moshe Vardi, Vice President and Global Medicine Team Lead at Alexion Pharmaceuticals, and Aleksandar Skuban, MD, Executive Medical Director for Neurology and Ophthalmology Clinical Development and Translational Sciences at Alexion Pharmaceuticals, Inc. Dr. Vardi explained the role of the immune system as it relates to GMD, or geographical atrophy. Dr. Skuban talked about studies being done to determine efficacy of new treatments, including danicopan, for GMD.

The event featured experts including Moshe Vardi, Vice President and Global Medicine Team Lead at Alexion Pharmaceuticals, and Aleksandar Skuban, MD, Executive Medical Director for Neurology and Ophthalmology Clinical Development and Translational Sciences at Alexion Pharmaceuticals, Inc. Dr. Vardi explained the role of the immune system as it relates to GMD, or geographical atrophy. Dr. Skuban talked about studies being done to determine efficacy of new treatments, including Danicopan, for GMD.

556: In this interview, Angela Yochem, the executive vice president and Chief Transformation & Digital Officer at Novant Health, and George Llado, the senior vice president and chief information officer of Alexion Pharmaceuticals, focus on the power of ecosystems. Angela discusses the importance of leveraging ecosystems to drive innovation at scale, and she shares the story of how Novant Health formed an “unconventional partnership” with Stewart-Haas to build ICU carts for overrun hospitals. Meanwhile, George discusses Alexion's strategy of cultivating relationships with startups and venture capital firms to accelerate innovation, as well as his approach to strategic planning.

In this interview, we discuss the company's journey from on-premise to the cloud and the benefits that provided, Alexion's secret sauce to change management, and the firm's close relationship with external partners. We discuss how George works with the VC community, including why Alexion invests in smaller companies, the risk George took on Zoom back in 2016, and the win-win partnership between Alexion and the smaller companies it invests in and works with. Lastly, we discuss some of the lessons George has taken from the pandemic, how the social injustices that came to light this year are not new, George's take on new and emerging digital tools, among a variety of other topics.